Nadofaragene firadenovec and the future of NMIBC care

Dr. Vikram M. Narayan describes treatment advances and next steps in non-muscle invasive bladder cancer.

Vikram M. Narayan, MD, of Emory University, Winship Cancer Institute, Atlanta, GA, discusses next steps with the novel intravesical gene-mediated therapy nadofaragene firadenovec and the overall future of the treatment paradigm for patients with non-muscle invasive bladder cancer (NMIBC).

Narayan says there are promising options, such as nadofaragene firadenovec, emerging for patients with BCG-unresponsive NMIBC. Some of the next steps, according to Narayan, are exploring combination regimens, assessing sequencing strategies, and developing biomarkers to determine which patients might respond best to treatments.